Key result
Epicardial fat may serve as an important biomarker for cardiovascular risk stratification in patients with chronic obstructive pulmonary disease.
Why the study?
COPD and cardiovascular diseases frequently coexist and worsen outcomes, prompting interest in whether epicardial fat can serve as a risk-stratification biomarker.
Does epicardial fat assessment improve cardiovascular risk stratification in patients with chronic obstructive pulmonary disease?
Does epicardial fat assessment improve cardiovascular risk stratification in patients with chronic obstructive pulmonary disease?
Epicardial fat may serve as a useful biomarker for identifying high cardiovascular risk in patients with COPD.
Should not yet change practice in COPD; leaves open epicardial fat as a biomarker pending prospective validation.
Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) are commonly interconnected, and this coincidence negatively influences patients' mortality and morbidity. On the basis of the current available data originating mainly from cardiovascular studies epicardial fat (EF) has been proposed as a marker of cardiovascular risk. This review is focused on a potential role of epicardial fat as a new biomarker for risk stratification of COPD patients. Epicardial fat may present an important link between chronic obstructive pulmonary disease and cardiovascular diseases, mainly coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Sova et al. (2018) conducted a review in Chronic obstructive pulmonary disease (COPD) and cardiovascular diseases. Epicardial fat was evaluated. Epicardial fat may serve as an important biomarker for cardiovascular risk stratification in patients with chronic obstructive pulmonary disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: